Craig Orla
Leeds Teaching Hospitals Trust, St James University Hospital, Leeds, West Yorkshire, England.
Curr Opin Gastroenterol. 2018 Jan;34(1):50-56. doi: 10.1097/MOG.0000000000000411.
The purpose of this review is to examine the evidence supporting the use of recently developed pharmacological treatments for IBS together with new evidence supporting more traditional therapies in order to understand where the new agents are best used in the treatment pathway.
There is evidence to support the use of traditional treatments such as antispasmodics, antidepressants and dietary alteration in IBS. New therapeutic agents such as Linaclotide, Lubiprostone, Plecanatide, Rifaxamin and Eluxadoline are all more effective than placebo in treating symptoms of IBS with Tenapanor being a promising new agent. The majority of patients, however, treated with these medications remain symptomatic and they are not suitable for use in all patients.
Traditional treatments such as antispasmodics, antidepressants, dietary and lifestyle modifications retain their importance in the treatment of IBS with the newer agents to be considered wherever these treatments are ineffective or poorly tolerated.
本综述旨在审视支持近期研发的用于肠易激综合征（IBS）的药物治疗的证据，以及支持更传统疗法的新证据，以便了解新药物在治疗路径中最适合应用的位置。
有证据支持在IBS中使用传统治疗方法，如抗痉挛药、抗抑郁药和饮食调整。新型治疗药物，如利那洛肽、鲁比前列酮、普卡那肽、利福昔明和艾度沙朵林，在治疗IBS症状方面均比安慰剂更有效，替那诺尔是一种有前景的新型药物。然而，接受这些药物治疗的大多数患者仍有症状，且它们并不适用于所有患者。
抗痉挛药、抗抑郁药、饮食和生活方式调整等传统治疗方法在IBS治疗中仍然很重要，在这些治疗无效或耐受性差的情况下应考虑使用新型药物。
